We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialise therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74.